With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.
With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.
TRIP gains access to the huge Brazilian market for its psilocybin truffles.
Optimi Health has commenced public trading (symbol "OPTI"). The Company raised CAD$20.7 million for its IPO financing.
PsyBio has commenced trading. Its focus is on drug development for the Mental Health Crisis.
MINDCURE's new Director is a veteran of capital markets.
MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
MINDCURE's first line of mushroom-based nootropics now available for sale.
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now